Hong Chen: “Noninvasive molecular diagnosis of brain cancer by sonobiopsy”
Aadel Chaudhuri: “SurgiSeq: A Novel Liquid Biopsy Platform for Minimal Residual Disease Detection after Surgery”
The Institute of Clinical and Translational Sciences (ICTS) Precision Medicine team invites you to an on-going collaboration with Venture Café. These sessions are hosted on the third Thursday of every month.
Hong Chen (WashU Biomedical Engineering/Radiation Oncology)
“Noninvasive molecular diagnosis of brain cancer by sonobiopsy”
Blood-based liquid biopsy is a promising noninvasive diagnostic technique to acquire a comprehensive molecular tumor profile by detecting cancer-specific biomarkers (e.g., DNA, RNA, and protein). However, there has been limited progress for brain tumor applications partially because of the blood-brain barrier (BBB), which hinders the release of brain tumor biomarkers. To address this unmet need, we developed sonobiopsy technique, which uses focused ultrasound to increase the BBB permeability and thus enhance the release of brain tumor-specific biomarkers into the bloodstream for the noninvasive molecular diagnosis of brain tumors by blood tests.
Aadel Chaudhuri (WashU Radiation Oncology)
“SurgiSeq: A Novel Liquid Biopsy Platform for Minimal Residual Disease Detection after Surgery“
SurgiSeq, an innovative approach to liquid biopsy analysis after cancer surgery for minimal residual disease detection.
For more information visit the ICTS Precision Medicine website.
Full schedule, Precision Medicine seminars